Get the Stockscreener App
10.18
0.00%
0.010
Drugs Made In America Acquisition Corp stock is traded at $10.18, with a volume of 441.
It is up +0.00% in the last 24 hours and up +0.59% over the past month.
Drugs Made In America Acquisition Corp is a blank check company.
See More
Previous Close:
$10.19
Open:
$10.18
24h Volume:
441
Relative Volume:
0.00
Market Cap:
$341.54M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.10%
1M Performance:
+0.59%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.18
$10.19
1-Week Range:
$10.17
$10.19
52-Week Range:
$9.96
$10.27
Drugs Made In America Acquisition Corp Stock (DMAA) Company Profile
Name
Drugs Made In America Acquisition Corp
Sector
Industry
Phone
954-870-3104
Address
2 PELICAN DR., FORT LAUDERDALE
Compare DMAA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAA
Drugs Made In America Acquisition Corp
|
10.18 | 341.54M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
5.645 | 1.91B | 2.82B | -191.60M | -407.10M | -0.6794 |
|
AACT
Ares Acquisition Corporation Ii
|
11.30 | 702.73M | 0 | 16.92M | -1.35M | 0.29 |
|
CCCM
Columbus Circle Capital Corp I
|
14.61 | 480.62M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.63 | 468.90M | 0 | 0 | 0 | 0.00 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.86 | 465.53M | 0 | 1.30M | 0 | 0.0301 |
Drugs Made In America Acquisition Corp Stock (DMAA) Latest News
Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - TradingView
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - Yahoo Finance
Trump says he is doubling tariffs on imported steel to 50% – as it happened - The Guardian
Pfizer Inc. - Britannica
Drugs Made In America Faces 10-Q Filing Delay - TipRanks
PCI Pharma Services Completes Ajinomoto Althea Acquisition - Contract Pharma
Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges - Business Wire
Financial Snapshot: Analyzing East West Bancorp, Inc (EWBC)’s Key Ratio Metrics - DWinneX
Metric Deep Dive: Understanding Drugs Made In America Acquisition Corp (DMAA) Through its Ratios - DWinneX
Market Resilience: Four Corners Property Trust Inc (FCPT) Finishes Weak at 27.86, Down -1.90 - DWinneX
Daily Progress: Coca-Cola Europacific Partners Plc (CCEP) Drop -0.78, Closing at 88.15 - DWinneX
Financial Analysis: Bio-Key International Inc (BKYI)’s Ratios Unveil Key Insights - DWinneX
Ratio Revelations: Amerant Bancorp Inc (AMTB)’s Financial Metrics in the Spotlight - DWinneX
Closing Strong: Lulus Fashion Lounge Holdings Inc (LVLU) Ends at 0.41, Down -7.73 from Last Close - DWinneX
What's Next for Pfizer After the Company Pulls Its Weight Loss Drug? - Yahoo Finance
The top 20 pharma companies by 2024 revenue - Fierce Pharma
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
WEBTOON Entertainment Inc. (NASDAQ:WBTN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Q1 2025 SPAC Market Update & Outlook - Business Wire
Theratechnologies’ stock soars on disclosure of acquisition offer by U.S. company - Montreal Gazette
Pharma’s US manufacturing moment: Where companies are making the biggest moves - Pharma Voice
10 Best Health Care Stocks to Buy for 2025 - US News Money
After saying overseas drugmakers would have a “big tax to pay,” Trump spares pharmaceuticals from reciprocal tariffs - Sherwood News
'I bought their dream': How a US company's huge land deal in Senegal went bust - Yahoo
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - Quartz
Bright Green Unveils Massive $2B Cannabis Strategy with Zero Shareholder Dilution - StockTitan
Bright Green Corporation Announces the next steps for the completion of its restructuring plan - The Manila Times
How TD Became America’s Most Convenient Bank for Money Launderers - Bloomberg.com
DRUGS MADE IN AMERICA ACQUISITION CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
India-based Syngene acquires its first US biologics site - Manufacturing Dive
Drugmakers Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger - Reuters
7 Best Weight Loss Drug Stocks to Buy in 2025 | Investing | U.S. News - U.S News & World Report Money
Not All Generics Are Created Equal: Study Exposes a 54% Higher Risk in Indian-Made Drugs - SciTechDaily
Brokerages Set TWFG, Inc. (NASDAQ:TWFG) Target Price at $31.86 - Defense World
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - Business Wire
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company - Eli Lilly
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - CNN
Drugs Made in America Acquisition Corp. Forms Advisory Team to Pursue Pharmaceutical Business Acquisitions - Nasdaq
How Vivek Ramaswamy got rich before going into politics - Cincinnati Enquirer
Popular cannabis brand declares Chapter 11 bankruptcy - TheStreet
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod - Fierce Pharma
Drugs Made In America Acquisition Corp. Announces Trading Options for Public Offering Units Starting February 25, 2025 - Nasdaq
Mink Ventures Completes Acquisition of Warren Ni, Cu, Co Patents - The Manila Times
Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option - TradingView
Drugs Made In America Acquisition Corp. Secures Additional $30 Million in IPO as Underwriter Fully Exercises Overallotment Option - Nasdaq
U.S. investors, Big Pharma race to find new medicines in China - CNBC
Drugs Made In America Acquisition Corp.’s $200 Million Initial Public Offering - Global Legal Chronicle
Drugs Made In America Acquisition Corp Stock (DMAA) Financials Data
There is no financial data for Drugs Made In America Acquisition Corp (DMAA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):